1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku’s JAK2 Inhibitor Earns Orphan Designation in US
December 21, 2022
- Daiichi Sankyo’s Blood Cancer Drug Ezharmia Now Available
December 21, 2022
- Breyanzi Now Approved in Japan for 2nd-Line Large B-Cell Lymphoma: BMS
December 21, 2022
- Chugai CEO Questions Off-Year Price Cuts for On-Patent Meds
December 21, 2022
- Janssen Japan Employees Form Labor Union to Counter Closing of Positions
December 21, 2022
- Chugai Eyes Submission of Oral GLP-1 Agent in 2025-2026: R&D Briefing
December 20, 2022
- Kissei Won’t Change 2025 Targets Despite Linzagolix Setback, Decide US Plan by March
December 20, 2022
- Enhertu Nabs EU Nod for Second-Line Gastric Cancer, CHMP OK for HER2 Low Breast Cancer
December 20, 2022
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- R&D Head Shiro Akinaga Becomes NanoCarrier President
December 19, 2022
- SymBio, Eagle Pharma Sue Towa over Treakisym Patent in Japan
December 19, 2022
- Sosei, Lilly in Drug Discovery Collab for Diabetes and Metabolic Diseases
December 19, 2022
- Astellas’s Zolbetuximab Makes Marks in Another PIII Gastric Cancer Study
December 19, 2022
- Pharma Industry Mixed on Off-Year Drug Price Revision Plan for FY2023
December 19, 2022
- PeptiDream, Takeda Expected to Select 1st Oligo-PDC Candidate in 2023
December 16, 2022
- Eisai, Washington University to Team Up on Neurodegenerative Disease Therapies
December 16, 2022
- Twymeeg Most Promoted Drug in GP Market for 4 Months Straight in October: Intage
December 16, 2022
- Sunovion Offloads Lunesta to Woodward Pharma
December 16, 2022
- Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan: Exec
December 15, 2022
- Daiichi Sankyo Plots Further Growth with Enhertu Follow-Ons, Eyes Next-Gen ADCs
December 15, 2022
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…